The importance of dual 5alpha-reductase
inhibition in the treatment of male pattern hair loss: results of a
randomized placebo-controlled study of dutasteride versus finasteride.
Dutasteride 2.5mg was clearly superior to Finasteride 5mg in reduction
of scalp and serum DHT (dihydrotestosterone) and showed superior hair
growth at 12 and 24 weeks.
J Am Acad Dermatol. 2006;
55(6):1014-23 (ISSN: 1097-6787)
Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S;
Ellis ML; Wilson T; Rittmaster RS;
Duke University Medical Center, Durham, North Carolina, USA.
BACKGROUND: Male pattern hair loss
(MPHL) is a potentially reversible condition in which
dihydrotestosterone is an important etiologic factor.
Our aim was to evaluate the efficacy of the type 1
and 2 5alpha-reductase inhibitor dutasteride in men with MPHL.
Four hundred sixteen men, 21 to 45 years old, were
randomized to receive dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride
5 mg, or placebo daily for 24 weeks.
Dutasteride increased target area hair count versus
placebo in a dose-dependent fashion and dutasteride 2.5 mg was superior
to finasteride at 12 and 24 weeks. Expert panel photographic review and
investigator assessment of hair growth confirmed these results. Scalp
and serum dihydrotestosterone levels decreased, and testosterone levels
increased, in a dose-dependent fashion with dutasteride.
LIMITATIONS: The study was limited to
Dutasteride increases scalp hair growth in men with
MPHL. Type 1 and type 2 5alpha-reductase may be important in the
pathogenesis and treatment of MPHL.